Janssen reports positive follow-up data from Phase III trial of Imbruvica for CLL

Janssen-Cilag International (Janssen) has reported positive data from a four-year follow-up period of its Phase III RESONATE trial of Imbruvica (ibrutinib) to treat relapsed / refractory (R/R) chronic lymphocytic leukaemia (CLL) patients.
Source: Drug Development Technology - Category: Pharmaceuticals Source Type: news